Page last updated: 2024-12-06
3,4-dimethoxyphenylacetonitrile
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3,4-dimethoxyphenylacetonitrile: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 66727 |
| SCHEMBL ID | 77974 |
| MeSH ID | M0105103 |
Synonyms (75)
| Synonym |
|---|
| einecs 202-225-1 |
| brn 1956100 |
| nsc 6324 |
| 3,4-dimethoxybenzeneacetonitrile |
| ai3-23882 |
| acetonitrile, 3,4-dimethoxyphenyl- |
| acetonitrile, 3,4-(dimethoxyphenyl)- |
| (3,4-dimethoxy-phenyl)-acetonitrile |
| BB 0240981 |
| 2-(3,4-dimethoxyphenyl)-acetonitrile |
| nsc6324 |
| 93-17-4 |
| acetonitrile,4-(dimethoxyphenyl)- |
| (3,4-dimethoxyphenyl)acetonitrile |
| homoveratronitrile |
| 3,4-(dimethoxyphenyl)acetonitrile |
| acetonitrile,4-dimethoxyphenyl)- |
| veratryl cyanide |
| benzeneacetonitrile,4-dimethoxy- |
| 3,4-dimethoxybenzyl cyanide |
| nsc-6324 |
| wln: nc1r co1 do1 |
| 3,4-dimethoxyphenylacetonitrile |
| acetonitrile, (3,4-dimethoxyphenyl)- |
| benzeneacetonitrile, 3,4-dimethoxy- |
| IFLAB1_000888 |
| OPREA1_832287 |
| (3,4-dimethoxyphenyl)acetonitrile, 98% |
| AKOS000199051 |
| 2-(3,4-dimethoxyphenyl)acetonitrile |
| HMS1414I08 |
| inchi=1/c10h11no2/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,7h,5h2,1-2h3 |
| aslsumisaqdoob-uhfffaoysa- |
| D1887 |
| 62c8s706sp , |
| ec 202-225-1 |
| 4-10-00-01513 (beilstein handbook reference) |
| unii-62c8s706sp |
| 2-(3,4-dimethoxyphenyl)ethanenitrile |
| (3,4-dimethoxyphenyl)acetonirile |
| F0255-0021 |
| FT-0614353 |
| AM20050420 |
| 3,4-dimethoxyphenyl acetonitrile |
| SCHEMBL77974 |
| 3,4-dimethoxy-phenyl-acetonitrile |
| (3,4-dimethoxyphenyl)-acetonitrile |
| [3,4-bis(methyloxy)phenyl]acetonitrile |
| 3,4-dimethoxyphenyl-acetonitrile |
| 3,4-dimethoxy phenylacetonitrile |
| 3,4-dimethyoxyphenylacetonitrile |
| 3,4-dimethoxy-benzyl cyanide |
| 3.4-dimethoxyphenylacetonitrile |
| W-100249 |
| 1219803-34-5 |
| 3,4-methyleneoxyphenyl acetonitrile |
| mfcd00001911 |
| DTXSID30239220 |
| GS-3047 |
| homoveratronitrile, purum, >=98.0% (gc) |
| CS-0008419 |
| SY012004 |
| 3,4-dimethoxy phenyl acetonitrile |
| 3,4-di methoxyphenylacetonitrile |
| EN300-20208 |
| STL195409 |
| BBL036932 |
| 2-(3,4-dimethoxyphenyl) acetonitrile |
| Q27263471 |
| 2-(2-chloro-acetylamino)-4-(3,4-dimethoxy-phenyl)-thiophene-3-carboxylicacidethylester |
| (3,4-dimethoxyphenyl)acetonitrile(homoveratronitrile) |
| 3,4-dimethoxyphenylacetonitirle |
| 3,4-dimethoxyphenylacetonitrile-a,a-d2 |
| Z104477288 |
| PD065604 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||